Mice transgenic for the leukemia oncogene E2A-PBX1 invariably develop lethal, high-grade T-cell lymphomas by 5 months of age. In this study, retroviral insertional mutagenesis was employed to identify oncogenes that cooperate with the E2A-PBX1 transgene in lymphomagenesis. Neonatal retroviral infection substantially reduced length of survival due to accelerated development of lymphomas (81 versus 130 days). The Pim1 gene was targeted by retroviral insertions in 48% of accelerated lymphomas whereas less than 5% contained activated cMyc and none contained activated Pim2. However, Pim1 DNA rearrangements were frequently sub-stoichiometric and not present at all sites of involvement in an otherwise monoclonal lymphoma indicating that Pim1 activation occurred late in the course of lymphomagenesis. Tumor subpopulations containing activated Pim1 alleles displayed a substantial growth advantage over Pim1 negative cells following serial transfer to secondary, syngeneic recipients. Cooperative interactions were observed in intercrossed Pim1 and E2A-PBX1 transgenic mice in which all double transgenic progeny developed lethal, diuse T lineage lymphomas by 3 months of age, whereas only 13% of E2A-PBX1 and none of Pim1 single transgenic intercross progeny developed lymphomas by 1 year. Tumors from double transgenic mice were monoclonal providing evidence that additional genetic events were required for transformation. Therefore, Pim1 and E2a-Pbx1 cooperate in T lineage lymphomagenesis but they are not sucient and the role of Pim1 is more likely to be associated with tumor progression.
Introduction
A signi®cant subset of chromosomal translocations in pre-B cell acute lymphoblastic leukemias of children results in the fusion of the E2A and PBX1 genes (Nourse et al., 1991; Hunger et al., 1991; Kamps et al., 1991) . The E2A gene codes for two dierentially spliced members of the helix ± loop ± helix family of transcription factors with essential roles in B lineage lymphopoiesis (Bain et al., 1994; Zhuang et al., 1994) . PBX1 codes for divergent homeodomain proteins that are implicated by genetic and biochemical studies to function as DNA binding cofactors for Hox proteins (Chang et al., 1995; Phelan et al., 1995; Lu et al., 1995) . Translocation-associated E2a-Pbx1 fusion proteins contain the transcriptional activation domains of E2a and the DNA-binding homeodomain of Pbx1. In gene transfer studies, E2a-Pbx1 fusion proteins display oncogenic eects in several dierent cell types, and, in some settings, have been shown to inhibit cellular dierentiation and induce apoptosis (Dedera et al., 1993; Kamps et al., 1991; Kamps and Wright, 1994; Monica et al., 1994) . Transgenic mice that express the E2A-PBX1 oncogene under control of the immunoglobulin heavy chain enhancer develop aggressive, high grade T lineage lymphoblastic lymphomas with a mean latency of approximately 4.5 months (Dedera et al., 1993) . All animals succumb to monoclonal lymphomas that appear to arise out of a premalignant state characterized by lymphoproliferation and apoptosis. The late emergence of clonal tumors indicates that, while E2a-Pbx1 can cause profound disruptions of thymocyte dierentiation and growth control, it is not sucient for malignant transformation. Additional, acquired mutations appear to be necessary for full oncogenic eects in this setting (Dedera et al., 1993) .
E2a-Pbx1 is representative of a small group of oncoproteins whose leukemogenic eects have been proposed to involve disruptions of Hox transcriptional regulatory pathways. E2a-Pbx1, like wild type Pbx proteins, has been shown to bind DNA in vitro as heterodimeric complexes with a wide variety of Hox proteins (Chang et al., 1995; Lu et al., 1995) . In addition, the oncogenic and transcriptional properties of E2a-Pbx1 are dependent on Pbx motifs that are also necessary for cooperative DNA binding with Hox partners . However, in contrast to wild type Pbx proteins, E2a-Pbx1 is a potent transcriptional activator (LeBrun and Cleary, 1994; Lu et al., 1994; van Dijk et al., 1993) suggesting that it may alter the transcriptional eector properties of Hox-Pbx complexes on subordinate downstream genes, whose identities remain to be determined. It is currently unclear how disruptions of Hox genetic pathways may contribute mechanistically to the oncogenic conversion of early lymphoid progenitors nor have the relationships of Hox regulatory pathways with other growth control pathways been determined.
In this study, we employed retroviral insertional mutagenesis (Adams and Cory, 1992; Berns et al., 1994) to search for cooperating oncogenes capable of decreasing the latency for development of thymic lymphomas in E2A-PBX1 transgenic mice. We demonstrate a marked acceleration in lymphomagenesis due to retroviral insertions that activate expression of the Pim1 gene. Cooperative interactions between these oncogenes was demonstrated in E2A-PBX1/Pim1 double transgenic mice, and the available evidence suggests that Pim1 contributes to lymphoma progression in this animal model.
Results
Neonatal M-MulV infection of E2a-Pbx1 transgenic mice accelerates the development of T-lineage lymphoblastic lymphomas
Ospring resulting from backcrosses of E2a-Pbx1 transgenic mice were injected neonatally with MMuLV to assess its eects on the development of T lineage lymphomas. As shown previously (Dedera et al., 1993) and con®rmed in this study, non-injected E2a-Pbx1 transgenic mice develop tumors with a mean latency of 130 days (Figure 1 ). In contrast, transgenic littermates injected neonatally with M-MuLV displayed a signi®cantly reduced latency (mean of 81 days). The survival of the latter cohort was also signi®cantly dierent from that displayed by M-MuLV-injected, non-transgenic FVB/N mice which exhibited a reduced survival compared to control animals (non-injected, non-transgenic) consistent with previous studies showing an approximate 30 ± 40% incidence of M-MuLVinduced lymphoma at 180 days (Cuypers et al., 1984) . No deaths were observed in the non-injected, nontransgenic control animals.
Tumors that developed in animals from all cohorts predominantly involved the thymus resulting in mediastinal compression and airway compromise. Massive splenic enlargement due to tumor involvement was always observed and metastatic spread to liver, kidney, lungs and other sites was frequently detected histologically. The tumors arising in MMuLV-infected E2a-Pbx1 mice displayed histologic features of diuse high-grade lymphomas that were indistinguishable from lymphomas that developed in non-injected E2a-Pbx1 mice (data not shown (Figure 2 ). One to four bands were observed per tumor (Figure 2 ) demonstrating that the lymphomas were monoclonal or oligoclonal in origin.
An acceleration of the lymphomagenic process following neonatal M-MuLV injection was also demonstrated by assessing the clonality of T-cells in the thymuses of animals sacri®ced prior to outward manifestations of disease. Southern blot analysis of bTCR gene con®gurations in thymic DNA demonstrated a clonal population of cells in the thymus at 6 weeks in transgenic animals neonatally injected with M-MuLV (Figure 3 ). In contrast, mice with either the transgene or M-MuLV alone displayed a polyclonal pattern of rearrangements in the thymus with no dominant clonal bands. By 8 weeks of age all tested transgenic M-MuLV-infected mice had clonal or oligoclonal rearranged bands in the thymus and usually in the spleen whereas non-injected E2a-Pbx1 mice rarely displayed clonal proliferations in the thymus and never in the spleen (data not shown). These results indicated that the development of clonal T cell proliferations occurred more rapidly following neonatal M-MuLV infections in E2a-Pbx1 transgenic mice consistent with the shortened survival of these animals. Haupt et al., 1991) . We therefore assessed the potential involvement of several genes (c-Myc, Pim1 and Pim2) known to be targeted at high frequencies by M-MuLV in thymic lymphomas in other settings van der Lugt et al., 1995) . By Southern blot analysis, 11 of 23 tumors (48%) from E2a-Pbx1 transgenic mice infected with M-MuLV demonstrated rearrangements of the Pim1 gene ( Figure 4 ). None of the lymphomas from non-injected E2a-Pbx1 transgenic mice (n=20) demonstrated genomic alterations of the Pim1 locus (data not shown). When examined for potential Myc gene alterations, two out of 40 tumors arising in MMuLV-injected transgenic mice showed evidence of cMyc gene rearrangement by Southern blot analysis whereas none contained Pim2 rearrangements (data not shown). These results indicated that Pim1 was frequently targeted by M-MuLV in E2a-Pbx1 transgenic mice and likely contributed to the shortened latency for T cell lymphoma development whereas cMyc was an infrequent target (the cases with c-Myc rearrangement lacked Pim1 alterations).
Cooperative interactions between E2a-Pbx1 and Pim1 transgenes leads to post-natal development of clonal T lineage lymphomas
The potential cooperative eects of Pim1 and E2a-Pbx1 in thymic lymphomagenesis were further investigated by analysing mice that were transgenic for both of these genes. E2a-Pbx1 transgenic mice were intercrossed with mice containing a Pim1 transgene driven by the H-2K promoter/M-MuLV LTR and maintained on a C57BL/Ka Thy1.1 background. Of the 58 total intercross ospring, a normal male : female ratio was obtained and the expected mendelian ratios of the various cohorts were observed ( Figure 5 ) con®rming that the Pim1/E2a-Pbx1 transgene combination was not lethal in utero. Animals from all cohorts appeared normal at birth and displayed normal post-natal development. However, at about 3 months of age 100% of the Pim1/E2a-Pbx1 double transgenic mice experienced lethargy, respiratory distress and abdominal distension. These physical signs resulted from the development of aggressive lymphomas which caused the demise of all animals in this cohort (mean survival 102 days). This contrasted with the E2a-Pbx1 single transgenic cohort, in which two of 15 animals (13%) succumbed to lymphoma (at 170 and 225 days) over a 1 year observation period and none of the 17 Pim1 single transgenic mice died. The dierence in survival between the E2a-Pbx1 and Pim1/E2a-Pbx1 mice was statistically signi®cant by students t-test (P50.0001). The incidence of lymphomas in the E2a-Pbx1 single transgenic mice resulting from this intercross was signi®cantly lower than reported above for inbred FVB/N mice harboring the E2a-Pbx1 transgene (Figure 1 ). We attribute this dierence to modi®er eects of the C57BL/6 genetic background on the oncogenic properties of the E2a-Pbx1 transgene. In spite of this, the two transgene combination of E2a-Pbx1 and Pim1 was considerably more potent for lymphoma induction resulting in a marked increase in incidence and shortened latency compared to E2a-Pbx1 single transgenic mice of the same genetic background. At autopsy, all E2a-Pbx1/Pim1 transgenic animals had evidence of diuse involvement with an aggressive lymphoma involving thymus, spleen, lymph nodes, bone marrow, liver, kidney, lung, and GI. Histologically, these lymphomas were indistinguishable from the lymphomas arising in E2a-Pbx1 mice (data not shown). Single transgenic animals sacri®ced at 1 year showed no histologic abnormalities. Southern blot analyses of TCR genes in DNA isolated from tumors that arose in E2a-Pbx1/Pim1 double transgenic animals demonstrated 1 ± 4 rearranged bands in each case indicative of mono-or oligoclonal origins for the tumors ( Figure  6 ). The clonal nature of the tumors indicated that the two transgenes were not sucient for lymphomagenesis and additional events were likely to be required, consistent with the observations that E2a-Pbx1/Pim1 mice did not develop perinatal tumors but, rather, succumbed to lymphomas after a 3 month latency period.
Activation of Pim1 occurs as a secondary event in MMuLV-associated lymphomas of E2a-Pbx1 mice Although retroviral insertions near Pim1 appeared to be a common event in M-MuLV accelerated lymphomas arising in E2a-Pbx1 transgenic mice, several observations suggested that activation of Pim1 may not be an early event in lymphomagenesis. Comparison of the hybridization intensities of rearranged versus germline Pim1 alleles in lymphoma DNAs with the corresponding ratios for bTCR alleles, often showed a reduced ratio for Pim1 (e.g. case #2, Figure 7a ). This suggested that Pim1 may be targeted in only a subpopulation of cells in a clonal tumor in contrast to cases in which Pim1 rearranged bands appeared to be stoichiometric with bTCR rearrangements (case #1, Figure 7a ). In a number of cases, it was also observed that Pim1 rearrangements were present in lymphoma cells from the thymus but not in clonally related tumor cells from the spleen of the same animal, a phenomenon also displayed by case #2 (Figure 7) . Consistent with the latter, Southern blot analyses for LTR integrations often showed additional bands in the thymus versus the spleen (e.g. cases #1 and 2, Figure  7b ) from the same animal. In other cases, no Pim1 rearrangements were detected in thymus or spleen and identical LTR display patterns were present in both sites (e.g. case #3, Figure 7a and b) . Finally, the frequency of Pim1 gene rearrangements was considerably lower in thymuses from 6 ± 8 week old animals prior to clinical manifestations of disease (25% versus 48% in moribund animals) in spite of the presence of a predominant clonal T cell proliferation in the thymus at this time point (Figure 3 ). Taken together, these observations suggested that Pim1 was targeted at a later time point in tumor evolution after the initial establishment of a clonal proliferation. However, in order to emerge as a clonal integration Pim1 must confer a selective advantage suggesting a potential role as a progression factor in some tumors.
Selective growth of lymphoma cells containing activated Pim1 following serial transfer to secondary recipients
The ability of Pim1 to emerge as a late integration site and provide a selective growth advantage in an established clonal lymphoma population was assessed by serial tumor transfers. Premorbid transgenic animals that had been injected with M-MuLV were sacri®ced and their tumors assessed for Pim1 gene rearrangements by Southern blot analysis. Cell suspensions (10 6 cells) were prepared from three monoclonal tumors that lacked detectable Pim1 gene rearrangements. Each of these was injected into three non-transgenic syngeneic FVB/N mice. This allowed for continued Figure 6 Lymphomas arising in E2a-Pbx/Pim1 double transgenic mice consist of monoclonal proliferations of T cells. TCRb gene con®gurations were assessed in DNA isolated from spleens of E2a-Pbx1/Pim1 mice that developed lymphoma. Rearranged gene fragments with a migration faster or slower than the germline band (dash) were detected in all cases compared to the negative control spleen (lane 4). The numbers of rearranged bands in each case were consistent with the presence of one or a few clonal T cell populations growth of the tumors under physiological selective pressure after the impending death of the primary animals. After a latency of approximately three weeks, two of three Pim1 7 primary tumors induced illness in the secondary host animals as evidenced by lethargy and abdominal extension. At autopsy, multiple lymphoid organs (thymus, spleen, and lymph nodes) were enlarged due to lymphoma involvement. Southern blot analyses of tumor DNAs using an LTR-speci®c probe demonstrated the presence of an additional integration in all tumors from secondary recipients that was not detectable in the primary tumor (Figure 8) . The LTR displays of the secondary tumors were identical to the primary tumor except for the additional integration demonstrating that the primary and secondary tumors were clonally related to each other. The appearance of an additional LTR integration coincided with the detection of a new Pim1 gene rearrangement in the same tumor tissues (Figure 8 ). It is of note that all tissue samples where tumor cells had invaded in the secondary host animals contained an identical Pim1 gene rearrangement. These data were most consistent with the presence of an undetectable subpopulation of cells in the primary tumors that contained a Pim1 gene rearrangement which conferred a substantial growth advantage in the secondary recipients.
Discussion
We present several lines of evidence indicating that Pim1 cooperates with E2a-Pbx1 in thymic lymphomagenesis. Enzyme: EcoRV Figure 8 Southern blot analyses of Pim1 gene con®gurations in lymphomas arising in secondary recipients. Southern blot analyses were conducted on tissues from the primary tumor (P) and sites of tumor involvement in secondary host animals (1 and 2) following serial transfers. DNA probes and enzyme digestions were the same as in Figure 7 . Arrows indicate new bands in tumor tissues from secondary recipients. RN, right inguinal lymph node; LN, left inguinal lymph node; T, thymus; G, gastric lymph node for cooperative interactions between Pim1 and E2a-Pbx1 was further demonstrated by their abilities to induce lethal thymic lymphomas in double transgenic mice expressing both genes in the T cell compartment. Several observations, however, indicated that in both settings, the combination of Pim1 and E2a-Pbx was not sucient for lymphomagenesis underscoring the need for additional genetic events. In some cases, it was clear that Pim1 activation occurred after the lymphoproliferation had established monoclonality. These studies extend the spectrum of oncogenes with which Pim1 cooperates and suggest a previously unencountered role for Pim1 in tumor progression with potential implications for the molecular events leading to transformation of lymphoid cells by E2a-Pbx1. Both Pim1 and E2a-Pbx1 provide potent, though distinct signals for proliferation in lymphoid cells. E2a-Pbx1 chimeric proteins appear to function as aberrant transcription factors which induce proliferation, inhibit dierentiation and render lymphoid cells more susceptible to apoptosis (Dedera et al., 1993; Kamps and Wright, 1994) . Mice transgenic for E2a-Pbx1 have marked increases in thymocyte proliferation and experience a 100% incidence of lethal thymic lymphoblastic lymphomas by 4 ± 5 months of age (Dedera et al., 1993) although, as shown in the current study, lymphoma incidence is substantially modi®ed by the genetic background. Curiously, in spite of the frequent association of E2a-Pbx1 with human B cell progenitor leukemias, experimental transformation of this cell type has not been obtained, perhaps due to their rapid apoptotic responses following forced expression of E2a-Pbx1 (Smith et al., 1997) .
Aberrant expression of Pim1 in transgenic mice results in mild splenomegaly, but no gross changes in lymphocyte production or dierentiation (Domen et al., 1993b) . Animals expressing Pim1 under control of the immunoglobulin heavy chain promoter have a low incidence of T-cell lymphomas . However, the incidence of malignancy can be accelerated by exposure to chemical carcinogens, radiation or retroviral infection (Breuer et al., 1989 (Breuer et al., , 1991 Sorensen et al., 1996) . Pim1 transgenic mice are approximately 25-fold more susceptible to carcinogeninduced lymphomas than control mice and these tumors frequently overexpress c-myc or have ras mutations (Breuer et al., 1989) . Conversely, M-MuLV infection of Pim-1 transgenic mice frequently results in proviral insertion into the locus for c-or n-Myc . Ospring transgenic for both c-Myc and Pim1 develop an aggressive lymphoproliferative disorder and die in utero demonstrating a potent synergy between these oncogenes . Acceleration of Pim1-associated tumorigenesis was also observed in mice transgenic for both Pim1 and Bcl-2 (Acton et al., 1992) . Therefore, Pim1 can cooperate with several oncogenes, each aecting dierent cellular pathways.
These studies were initiated with the aim of elucidating the molecular mechanisms of E2a-Pbx1 function by identifying genes of known function with which it cooperates in lymphomagenesis. Although considerable data support the oncogenic role for Pim1, its ultimate contributions to lymphoid growth control remain unknown. Pim1 is a cytoplasmic serinethreonine kinase (Hoover et al., 1991) whose expression levels vary throughout the cell cycle increasing during progression from early to late G1 and remain high at the G1/S transition (Liang et al., 1996) . In addition, Pim1 modulates the IL-3 signal transduction pathway and appears to be a determining factor in the ability of cells to respond to IL-7 and steel factor, and therefore is an important regulator of early B cell lymphopoiesis (Domen et al., 1993a,b; Lilley et al., 1992) . Pim1 expression is controlled via the Jak/STAT pathway and STAT 5, in particular, has been shown to regulate Pim1 expression (Muli et al., 1996) . The Jak kinases and associated STAT factors are important components of many cytokine receptor signaling cascades and their aberrant regulation has been implicated in a variety of cancers of hematopoietic cells (Matsumura et al., 1997; Giordano et al., 1997; Dent et al., 1997; Ilaria and Van Etten, 1996) . Furthermore, inhibition of Jak activity blocks leukemic cell growth in vitro and in vivo by inducing apoptosis of ALL cells while having no eect on normal cells (Meydan et al., 1996) .
Pim1 has been tentatively linked with malignant growth potential and factor dependence in studies of rat Nb2-11 lymphoma cells in which a subline (Nb2-SFJCD1) is capable of prolactin-independent growth but when treated with sodium butyrate reverts to factor dependence, less malignant growth and decreased Pim1 and c-Myc expression (Buckley et al., 1996) . Thymocytes transformed by E2a-Pbx1 appear to be highly dependent on unidenti®ed cytokines as evidenced by their propensity to quickly undergo apoptosis following explantation (Dedera et al., 1992) . Similarly, myeloid cells transformed in vitro by E2a-Pbx1 retain their dependence on cytokines for in vitro growth and survival (Kamps and Wright, 1994) . Therefore, secondary mutations that abrogate cytokine dependence could provide a substantial growth advantage and perhaps help suppress the eect of E2a-Pbx1 to render lymphoid cells more susceptible to apoptosis. This would be consistent with the secondary nature of Pim1 activation observed in our studies since mutations that contribute to reduced cytokine requirements would not be necessary for initiation of malignant proliferation but may be conducive to more aggressive growth as the tumor evolves.
The ability of E2a-Pbx1 to cooperate with Pim1 in lymphomagenesis provides yet another feature that it shares with c-Myc. Both genes are associated with human B-lineage leukemias as targets of chromosomal translocations in distinctive subsets of ALL. Both encode nuclear proteins with features of transcription factors that induce rapid development of aggressive lymphoid malignancies at high frequencies in transgenic mice. Both proteins have been shown to render cells highly susceptible to apoptosis and their oncogenic properties are substantially enhanced by coexpression of suppressors of apoptosis (Strasser et al., 1990 and unpublished observations) . Thus, E2a-Pbx1 appears to function analogously to c-Myc as a nuclear oncoprotein. However, the cooperative interactions of Pim1 with E2a-Pbx1 do not appear as potent as with cMyc, one of the more powerful oncogene synergisms reported to date. This may re¯ect dierences in their molecular mechanisms of action (e.g. target genes) and perhaps accounts for our observations that Pim1 activation can arise later in the course of lymphomagenesis induced by E2a-Pbx1.
Our studies con®rm that the acquisition of viral integrations in transgenic models of ALL is a dynamic process that continues even after a clonal tumor has arisen. Secondary integrations are likely to provide selective advantages to tumor subclones, a feature that has been exploited to identify Frat-1, a novel gene associated with tumor progression in M-MuLVinfected c-Myc transgenic mice (Jonkers et al., 1997) . Activation of Pim1 in E2a-Pbx1 mice shares features with Frat-1 activation as a secondary event that confers substantial selective growth advantages. In the current study, Pim1 gene rearrangements were frequently substoichiometric or present at only one of several sites of involvement in an otherwise monoclonal tumor. However, occult tumor subclones with Pim1 gene activation rapidly emerged as the dominant tumor clone upon transfer to secondary recipients. Further evidence to support the secondary nature of Pim1 activation derives from the decreased incidence of Pim1 integrations (25% vs 48%) when animals were sacri®ced at time points considerably prior to death from tumors but when monoclonal proliferations were already present (data not shown). Taken together, these observations suggest a role in some cases for Pim1 during progression. The clonality of tumors arising in double transgenic mice is consistent with this conclusion providing evidence that Pim1 and E2a-Pbx1 are not sucient for lymphomagenesis and that additional (epi)genetic events are required for full transformation.
Materials and methods

Transgenic mice
E2a-Pbx1 transgenic mice (line Tg.E2a-Pbx1a as reported by Dedera et al. (1993) ) were maintained on an FVB/N inbred background. The transgene consisted of the E2a-Pbx1a cDNA linked to the immunoglobulin heavy chain enhancer and V H promoter. Only male ospring of this line expressed the transgene due to its integration on the Y chromosome. The Pim1 transgenic line (Breuer et al., 1989) was maintained on a C57BL/Ka, Thy1.1 inbred background. The Pim1 transgene consisted of the Pim1 gene linked to an H-2K promoter and Moloney MuLV LTR. Neonatal ospring (52 days of age) from backcrosses of E2a-Pbx1 mice were injected intraperitoneally (i.p) with MMuLV (10 5 p.f.u. in 4100 ml in RPMI) obtained from the American Type Culture Collection (strain E-286). For serial transfers of lymphomas to secondary recipients, thymic tumors were removed from primary recipients and single cell suspensions generated by manual disruption in PBS. Cell counts were determined by vital dye staining and 10 6 viable lymphoma cells were injected i.p. into inbred FVB/N recipients.
Characterization of tumors
Southern blot analyses were performed on DNA isolated from lymphomatous tissues as reported previously (Dedera et al., 1993) . For assessment of T cell receptor beta chain gene rearrangements, DNA was digested with EcoRI. For detection of Pim1 DNA rearrangements, EcoRV-digested DNA was hybridized with a 1.1 kb fragment of the Pim1 gene (Domen et al., 1993c) . A 560 bp fragment of the MMuLV LTR was employed on EcoRI+NheI-digested DNA for evaluation of retroviral integration sites. Tumor tissues were removed and preserved in buered formalin and processed for routine histology.
